2005

2005 INTERCEPT Conference Abstracts

 

Jump to Conference
EBMT ISBT Athens ISBT Bangkok
EHA DGTI ASH
SFTS AABB  



European Group for Blood and Marrow Transplantation (EBMT)
March 2005 |
Prague, Czech Republic

  • Roback J, Lin L, Corash L. Prevention of transfusion-transmitted CMV infection: a murine model.

European Hematology Association (EHA)
June 2005 | Stockholm, Sweden

  • Sawyer L, Mababangloob R, Propst M et al. Inactivation of blood-borne pathogens in apheresis plasma and platelets using the INTERCEPT Blood System.

Society of French Transfusion Sanguine (SFTS)
June 2005 | St. Malo, France

  • Lass-Flörl C, Allersdorfer D, Rheinschmidt M et al. Comparative efficacy of bacterial culture versus pathogen inactivation to reduce the risk of transfusion-associated sepsis.
     
  • Osselaer J, Messe N, Goffaux M et al. Une expérience de 15 mois d'utilisation d'INTERCEPT pour l'inactivation des agents pathogènes dans les concentrés plaquettaires.
     
  • Corash L, Sawyer L, Mababangloob R et al. Inactivation of blood-borne pathogens in apheresis plasma and platelets using the INTERCEPT Blood System.
     
  • Jauneau, Le Quere S, Leaute AG et al. Evaluation in vitro de concentres de plaquettes d'apherese (cpa) preleves sur separateur spectra et inactives par intercept blood system apres reduction du volume de plasma.
     
  • Van Haute I, Benoit Y, Vandecruys E et al. Safety and effi cacy of pathogen-inactivated platelets transfused in routine use to pediatric patients: an interim report.

International Society of Blood Transfusion (ISBT)
July 2005 | Athens, Greece 

  • Simonsen AC, Johansson PI, Flament J et al. Transfusion of thrombocytopenic patients using INTERCEPT platelets prepared with photochemical treatment with amotosalen and UVA light and stored for 7 days: results of a pilot study.
     
  • Lass-Flörl C, Allersdorfer D, Rheinschmidt M et al. Comparative efficacy of bacterial culture versus pathogen inactivation to reduce the risk of transfusion-associated sepsis.
     
  • Osselaer JC, Bueno JL, Messe N et al. Prospective active hemovigilance plan for INTERCEPT platelets in Europe: a status report.
     
  • Santos G, Silva C, Pereira F et al. Validation of INTERCEPT treatment of pooled platelets.

German Society of Transfusion Medicine and Immunohaematology (DGTI)
September 2005 |
Erfurt, Germany

  • Lass-Flörl C, Allersdorfer D, Rheinschmidt M et al. Bacterial contamination of platelets - screen or inactivate?

American Association of Blood Banking (AABB)
October 2005 |
Seattle, Washington, USA    

  • Pinna D, Lin L, Vicenzi E. Photochemical inactivation of SARS-CoV in platelet concentrates: comparison of a PCR inhibition assay to an infectivity assay.
     
  • Van Haute I, Benoit Y, Vandecruys E et al. Therapeutic effi cacy and safety of transfusion of pathogen-inactivated platelets to pediatric patients.
     
  • Lass-Flörl C, Allersdorfer D, Rheinschmidt M et al. Comparison of BactAlert® and INTERCEPT™ in preventing the release of platelet units containing low numbers of viable bacteria.
     
  • Lozano M, Arenillas L, Perea D et al. Pilot study of routine use of INTERCEPT treated buffy coat derived platelet concentrates.
     
  • Curtis B, Graminske S, Lochowicz A et al. Conservation of human platelet antigen (HPA) immunologic identity after photochemical treatment of platelet components with amotosalen (S-59) and UVA light.

International Society of Blood Transfusion (ISBT)
November 2005 |
Bangkok, Thailand   

  • Sawyer L, Mababangloob R, Propst M et al. Inactivation of blood-borne pathogens in apheresis plasma and platelets using the INTERCEPT blood system.
     
  • Conlan M, Vesole D, Stadtmauer E et al. Source of donor stem cells impacts incidence of bleeding and platelet and RBC transfusion requirements during stem cell transplantation: results of the phase III Sprint trial of INTERCEPT platelets.

American Society of Hematology (ASH)
December 2005 |
Atlanta, Georgia, USA  

  • Castro E, Gironés N, Bueno JL et al. The efficacy of photochemical treatment with amotosalen and UVA (INTERCEPT) inactivation of T. cruzi in buffy coat platelet components.
     
  • Lozano M, Galan A, Mazzara R et al. Leucocyte-reduced buffy coat platelet concentrates (BCPC) treated with INTERCEPT stored up to 7 days: hemostatic function in a whole blood flow system.
     
  • Osselaer JC, Doyen C, Messe N et al. Routine use of platelet components prepared with photochemical treatment (INTERCEPT platelets): impact on clinical outcomes and resources.
Untitled Document